Article
What We're Reading: Industry Ties to Research; Balance Billing Woes; Marijuana Research Stalled
Author(s):
Memorial Sloan Kettering Cancer Center’s chief executive emailed all staff telling them they “need to do a better job” of disclosing industry relationships in the wake of a published report that the cancer center’s chief medical officer failed to disclose his extensive industry ties; the remedy to balance billing (the surprise bills patients receive after their insurance plan has paid the contracted amount with a provider) may lie at the federal or state level or possibly the courts; marijuana health research applications are stalled at the Drug Enforcement Administration, 2 years after it began taking the requests.
MSKCC Tells Staff to Improve Disclosures of Industry Ties to Faculty
Memorial Sloan Kettering Cancer Center’s chief executive emailed all staff telling them they “need to do a better job” of disclosing industry relationships in the wake of a published report that the cancer center’s chief medical officer failed to disclose his extensive industry ties in dozens of research articles since 2013. The New York Times said the email referred to an article published over the weekend by the paper and ProPublica. The article found that José Baselga, MD, had received millions of dollars in consulting fees and ownership interests in healthcare companies, but he did not mention those ties in appearances at scientific conferences and in journal articles.
Protections for Balance Billing Don't Apply to Self-Funded Plans
The remedy to balance billing (the surprise bills patients receive after their insurance plan has paid the contracted amount with a provider) may lie at the federal or state level or possibly the courts, Kaiser Health News reported. Kaiser examined one facet of the issue as it applies to self-funded plans under the federal Employee Retirement Income Security Act of 1974, or ERISA. ERISA does not prohibit balance billing, even as more states move to protect consumers against surprise medical bills.
DOJ Not Processing Applications for Marijuana Health Research, Lawmakers Say
Marijuana health research applications are stalled at the Drug Enforcement Administration, 2 years after it began taking the requests, The Wall Street Journal reported. The Department of Justice, led by Attorney General Jeff Sessions, a longtime critic of marijuana use, is not eager to process the applications, leading to bipartisan frustration. Researchers, including those working with veterans, want to study a wider variety of marijuana to know if it can be effective in alleviating pain, fighting seizures, combating depression, or relieving posttraumatic stress.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
